Recombinant Human SIRPA Protein，His

SIRPA (Innate Immune Receptor Protein A) is a crucial receptor predominantly expressed on myeloid cells, playing a significant role in the regulation of immune responses. This receptor mediates various cellular processes, including phagocytosis and the regulation of immune signaling pathways, particularly through its interaction with the CD47 "don't eat me" signal, which inhibits macrophage-mediated phagocytosis of self-cells. Recent studies have highlighted the potential of SIRPA as a therapeutic target in cancer immunotherapy, as blocking the CD47-SIRPA interaction can enhance the clearance of tumor cells by the immune system. Furthermore, the understanding of SIRPA's structural biology and its downstream signaling mechanisms is essential for the development of engineered SIRPA proteins or antibodies that can boost anti-tumor immunity. By investigating the recombinant SIRPA protein, researchers aim to elucidate its functional properties and further explore its applications in both basic immunology and clinical settings. The insightful manipulation of SIRPA could pave the way for next-generation treatments that not only enhance immune responses against cancer but also mitigate the immunosuppressive environments often created by tumors. Such advancements could lead to more effective therapies in cancer treatment, significantly improving patient outcomes in oncology. As a result, the study of SIRPA and its recombinant forms stands at the forefront of contemporary immunological research, offering promising avenues for innovative therapeutic interventions.